On October 22, 2025 Boston Scientific Corporation (NYSE: BSX) reported net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported basis, 19.4 percent on an operational1 basis and 15.3 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $755 million or $0.51 per share (EPS), compared to $469 million or $0.32 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.63 a year ago.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We delivered another exceptional quarter of strong performance across businesses and regions thanks to the winning spirit of our global team," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "As we shared at our recent Investor Day meeting, we are well-positioned for differentiated growth that is fueled by our category leadership strategy, relentless focus on innovation and commitment to scaling capabilities."
Third quarter financial results and recent developments:
Reported net sales of $5.065 billion, representing an increase of 20.3 percent on a reported basis, compared to the company’s guidance range of 17 to 19 percent; 19.4 percent on an operational basis; and 15.3 percent on an organic basis, compared to the company’s guidance range of 12 to 14 percent, all compared to the prior year period.
Reported GAAP net income attributable to Boston Scientific common stockholders of $0.51 per share, compared to the company’s guidance range of $0.44 to $0.46 per share, and achieved adjusted EPS of $0.75 per share, compared to the guidance range of $0.70 to $0.72 per share.
Achieved the following net sales growth in each reportable segment, compared to the prior year period:
MedSurg: 16.4 percent reported, 15.6 percent operational and 7.6 percent organic
Cardiovascular: 22.4 percent reported, 21.5 percent operational and 19.4 percent organic
Achieved the following net sales growth/(declines) in each region, compared to the prior year period:
United States (U.S.): 27.0 percent reported and operational
Europe, Middle East and Africa (EMEA): 2.6 percent reported and (2.0) percent operational
In the second quarter of 2025, management made the decision to discontinue worldwide sales of the ACURATE neo2 and ACURATE Prime Aortic Valve Systems, which had prior year global sales of approximately $50 million per quarter
Asia-Pacific (APAC): 17.1 percent reported and 16.9 percent operational
Latin America and Canada (LACA): 10.4 percent reported and 9.6 percent operational
Emerging Markets4: 11.8 percent reported and 11.5 percent operational
Announced Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for expanded labeling of the FARAPULSE Pulsed Field Ablation (PFA) System to include treatment of drug refractory, symptomatic persistent atrial fibrillation (AF).
Commenced enrollment in the AGENT DCB STANCE trial to assess the safety and effectiveness of the AGENT Drug-Coated Balloon (DCB) in patients with previously untreated coronary lesions, compared to standard of care percutaneous coronary intervention (PCI) treatment with drug-eluting stents and/or balloon angioplasty.
Published in JAMA Neurology outcomes from the five-year INTREPID study demonstrating sustained benefits of deep brain stimulation in people with moderate to advanced Parkinson’s disease, including improved motor function and quality of life.
Completed asset acquisition with Elutia, Inc. to acquire the antibiotic-eluting EluPro BioEnvelope and the CanGaroo Envelope, designed to prevent certain post-operative complications for devices such as pacemakers and defibrillators.
Announced agreement to acquire Nalu Medical, Inc., developer of the Nalu Neuromodulation System, which is designed to use peripheral nerve stimulation to deliver targeted relief for adults living with severe, intractable chronic pain of peripheral nerve origin — subject to customary closing conditions.
(Press release, Boston Scientific, OCT 22, 2025, View Source [SID1234661705])